<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport has Been Engaged by Roslin Cells for Logistics Support of Roslin’s iPSC service

March 31, 2015

Lake Forest, CA, March 31, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been engaged to provide its cryogenic logistics services to Roslin Cells of Edinburgh, United Kingdom in support of Roslin’s induced pluripotent stem cell  (iPSC) reprogramming service.

Roslin Cells is a global leader in the development and production of human pluripotent stem cell lines to the life science community for the development of new reagents, drugs and cellular therapeutics.  It is also establishing the Central Facility for the European Bank for induced stem Cells (EBiSC) as part of a €35 million program funded by the Innovative Medicines Initiative. This aims to be the primary resource in Europe for high quality iPSCs.

As an effective and reliable liquid nitrogen vapor phase (LNVP) logistics solution is critical to any cell based research program, Cryoport’s cryogenic logistics services are well positioned to support this burgeoning research area that the life sciences industry believes is critical to addressing many diseases.

Mr. Aidan Courtney, CEO of Roslin Cells, commented, “Our vision is to establish a robust and cost effective capacity to receive high quality iPSC samples from researchers across Europe and to be able to distribute them globally.  Cryoport’s technology and capabilities provide validated cryogenic cold chain logistics solutions which will allow us to realize these goals.”

Mr. Jerrell Shelton, Cryoport’s CEO, stated, “As we further expand our operations in the European Union, Cryoport takes great pride in having the opportunity to support Roslin Cells in its continuing development and manufacture of pluripotent stem cells for the life sciences community. This relationship builds on our success to support leading cell therapy programs and demonstrates our position in regenerative medicine in Europe.  Cryoport believes that iPSC research will play a significant role in developing therapeutic options for patients into the future and we are delighted to support Roslin Cells in our critical cryogenic logistics role.”

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or  Android mobile device.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Investor Contacts:
Todd Fromer / Garth Russell
tfromer@kcsa.com / grussell@kcsa.com
P: 1 212-682-6300

Tags: Press Releases, News, Dry Shipper, Frozen Shipping, frozen shipping solution, Cold Chain Logistics, Cancer, Roslin, iPSC, pluripotent stem cell, reprogramming